Lantern Pharma Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-10.4%projected annual EPS growth
Analyst Coverage
2analysts covering
FY EPS (est.)
-$1.51next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| LP-300 HARMONIC Trial Clinical Data Updates | 31 Dec 2026 |
Monitoring Framework
Key Performance Indicators
RADR AI Platform Oncology Data Points Quarterly200BTarget: Continued expansion of data points to enhance predictive accuracy
Cash, Cash Equivalents, and Marketable Securities Quarterly6.3MTarget: Maintain sufficient runway to fund operations into Q1 2027
LP-300 HARMONIC Phase 2 Trial Enrollment QuarterlyTarget: Complete enrollment under amended protocol
Watch Items
- LP-300 HARMONIC Trial Protocol Amendments ImplementationTrigger: FDA Type C meeting concurrence received with no objections in May 2026Action: Implement protocol amendments including narrowing enrollment to EGFR exon 21 L858R mutation and extending treatment cycles
- Commercialization of withZeta.ai PlatformTrigger: Commercial launch initiated in early 2026Action: Monitor subscription and usage-based revenue generation and progress strategic plan to spin off withZeta.ai assets into an independent entity
- Cash Runway and Going Concern RiskTrigger: Pro forma liquidity expected to fund operations into the middle of Q1 2027Action: Pursue additional non-dilutive funding, partnerships, or capital raises to extend operating runway
Research as of 20 Jun 2026